Sign In
Buy EWTX
$36.21
-1.04 (-2.79%)
At Close: Jun 03, 2026
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
04:01pm, Wednesday, 03'rd Jun 2026
BOULDER, Colo., June 3, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics
Edgewise Therapeutics Stock Hits Record High on $2.65B Servier Deal
12:15pm, Tuesday, 02'nd Jun 2026
EWTX surges 18% to a record high after striking a $2.65 billion neuromuscular business divestiture deal with Servier, sharpening focus on its cardiovascular pipeline.
Edgewise to sell muscle dystrophy business to Servier for up to $2.65 billion
08:34am, Monday, 01'st Jun 2026
Biotech firm Edgewise Therapeutics said on Monday it would sell its experimental muscular dystrophy drug and related business to France's Servier for up to $2.65 billion.
— Edgewise to Receive $1.55 Billion in Upfront Cash Consideration and is Eligible to Receive up to $1.1 Billion in Regulatory and Commercial Milestones — — Transaction Creates Focused Cardiovasc
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026
08:00am, Tuesday, 12'th May 2026
BOULDER, Colo., May 12, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that Edgewise leadership will present at th
– Announced positive long-term sevasemten data demonstrating sustained functional stabilization in Becker muscular dystrophy (Becker) up to 3.5 years of follow-up – – CIRRUS-HCM 12-week data
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
08:00am, Monday, 04'th May 2026
BOULDER, Colo., May 4, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics
Contrasting ABVC BioPharma (NASDAQ:ABVC) and Edgewise Therapeutics (NASDAQ:EWTX)
01:12am, Monday, 27'th Apr 2026
ABVC BioPharma (NASDAQ: ABVC - Get Free Report) and Edgewise Therapeutics (NASDAQ: EWTX - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two compani
Edgewise Therapeutics (NASDAQ:EWTX) Reaches New 12-Month High – Should You Buy?
04:57am, Tuesday, 07'th Apr 2026
Edgewise Therapeutics, Inc. (NASDAQ: EWTX - Get Free Report) shares hit a new 52-week high on Tuesday. The stock traded as high as $34.00 and last traded at $32.83, with a volume of 577238 shares trad
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Consensus Recommendation of “Moderate Buy” by Analysts
02:38am, Monday, 06'th Apr 2026
Shares of Edgewise Therapeutics, Inc. (NASDAQ: EWTX - Get Free Report) have been given an average rating of "Moderate Buy" by the ten research firms that are currently covering the company, MarketBeat
SG Americas Securities LLC Buys 78,842 Shares of Edgewise Therapeutics, Inc. $EWTX
04:45am, Sunday, 05'th Apr 2026
SG Americas Securities LLC raised its position in shares of Edgewise Therapeutics, Inc. (NASDAQ: EWTX) by 797.9% during the fourth quarter, according to its most recent Form 13F filing with the Securi
Edgewise Therapeutics (NASDAQ:EWTX) CMO Joanne Donovan Sells 28,662 Shares
04:48am, Friday, 03'rd Apr 2026
Edgewise Therapeutics, Inc. (NASDAQ: EWTX - Get Free Report) CMO Joanne Donovan sold 28,662 shares of the business's stock in a transaction that occurred on Wednesday, April 1st. The shares were sold
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
08:00am, Wednesday, 01'st Apr 2026
BOULDER, Colo., April 1, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutic
Why Edgewise Therapeutics Stock Topped the Market on Tuesday
06:31pm, Tuesday, 17'th Mar 2026
She raised her price target by $11 per share. In her view, the company's No.
The $3B Biotech With Two Shots On Goal
07:07am, Tuesday, 17'th Mar 2026
A cleaner drug, zero competition, and two binary readouts this year. Plus, Powell and oil near $99.
